Pattern recognition receptors (PRRs) protect against host invasion by detecting specific 35 molecular patterns found in pathogens and initiating an immune response. While 36 microbial-derived PRR ligands have been extensively characterized, the contribution and 37 relevance of endogenous ligands to PRR activation during viral infection remain 38 overlooked. In this work, we characterize the landscape of endogenous ligands that 39 engage RIG-I-like receptors (RLRs) upon infection by a positive-sense RNA virus, a 40 negative-sense RNA virus or a retrovirus. We found that several endogenous RNAs 41 transcribed by RNA polymerase 3 (Pol3) specifically engage RLRs, and in particular the 42 family of small non-coding repeats Y-RNAs, which presents the highest affinity as RIG-I 43 ligands. We show that this recognition is dependent on Y-RNA mimicking viral secondary 44 structure and its 5'-triphosphate extremity. Further, we found that HIV-1 infection triggers 45 a VPR-dependent downregulation of RNA triphosphatase DUSP11 in vitro and in vivo, 46 leading to an increase of Y-RNA 5'-triphosphorylation that enables their immunogenicity. 47
Importantly, we show that altering DUSP11 expression is sufficient to induce a type-I 48 interferon and T cell activation transcriptional program associated with HIV-1 infection. 49
Overall, our work uncovers the critical contribution of endogenous repeat RNAs ligands to 50 antiviral immunity and demonstrates the role of this pathway in HIV-1 infection. 51 statistical evaluation of specific binding (15, 16) . We performed an unbiased quantification 82 of RLR-bound self RNAs during RNA virus infection. We generated human HEK293 (293) 83 cells stably expressing the tagged-RLRs RIG-I, MDA5 or LGP2, or the protein Cherry as 84 non-binding control. We infected each cell line with either positive-sense RNA virus 85
Dengue Virus 4 (DV-4) or negative-sense RNA virus Measles Virus (MV). As a model of 86 retroviral infection, we co-cultivated HIV-1-infected MT4 T cells with 293 cells 87 overexpressing HIV-1 receptors CD4 and CXCR4 (293-4x4), as cell-free HIV-1 particles 88 are poor stimulators of type I interferon (IFN-I) (17). We performed total RNA-sequencing 89 on each RLR-or Cherry-purified fraction and on total cellular RNA ( Fig. S1A) . Importantly, 90
we confirmed that the RLR-MAVS pathway is critical for sensing each viral infection in this 91 model ( Fig. 1A, Fig. S1B ). We previously reported specific viral RNA-binding profiles on 92 RLR compared to non-specific binding (Cherry) upon MV and DV-4 infections (15, 16) 93 ( Fig. S1C-D) . However, upon HIV-1 infection, no enrichment of viral RNA was observed 94 on any receptors (Fig. S1E ). We then aligned RLR-bound RNAs to the human genome 95 and measured specific cellular RNA enrichments in infected and non-infected conditions. 96 Importantly, we found a strong enrichment of Pol3-transcribed RNAs to RIG-I and LGP2 97 upon each RNA virus infection, and in particular Y-RNAs ( Fig. 1B-C, Fig. S1F , S1H, Table  98 S1). Y-RNAs constitute a family of highly conserved small noncoding RNAs transcribed 99 by Pol3, composed of four canonical Y-RNA (RNY1, RNY3-5) and several hundreds of 100 pseudogenes (18). As the repetitive nature of Y-RNAs makes it impossible to identify the 101 exact origin of each transcript, we measured RLR enrichment of each repeat family rather 102 than individual genes ( Fig. 1D , S1G, S1I, Table S2 ). Specifically, the subfamily of HY4, 103 which contains RNY4 and its pseudogenes, and to a lesser extent HY3, showed significant 104 binding enrichment to RIG-I in the three RNA virus infections compared to non-infected 105 conditions (NI). 106 5'-PPP and a specific secondary structure are required for RNY4 RIG-I 107 agonist activity 108 To analyze the immunostimulatory properties of Y-RNAs, we generated in vitro 109 transcribed (IVT) molecules of each canonical Y-RNA and measured IFN-I signaling after 110 stimulation of individual RLR knock-outs generated in the haploid cell line HAP1. Each 111 individual Y-RNA was able to elicit an IFN-I response after transfection, which was 112 dependent on the presence of RIG-I and MAVS, but independent of MDA5 or to a large 113 extent LGP2 ( Fig. 2A ). Further, as cellular Y-RNAs are observed under two different 114 forms, a full-length form and shorter fragments derived from its 5′ and 3′ termini (18), we 115 compared RNY4 reads coverage between the fraction bound to RIG-I and the fraction 116 sequenced from the total cellular RNA pool in the different experimental infections 117 settings. Interestingly, we did not find significant differences between RIG-I-bound RNAs 118 and total cellular RNY4, and coverage results suggested that the uncleaved form of RNY4 119 controls its RIG-I binding property (Fig. S2A ). RIG-I recognizes RNA ligands based on a 120 level of specificity in terms of sequence composition, length, double-stranded structures, 121 and presence of triphosphate (-PPP) or diphosphate 5' moieties (14) . We generated 122 fragments derived from RNY4 missing specific molecular substructures ( Fig. S2B ). As 123 shown in Fig. 2B , both 5'-PPP and stem S3 were required to confer upon RNY4 its RIG-I-124 dependent immunostimulatory activity. 125
To validate these findings, we synthesized IVT RNY4 and RNY4ΔS3 RNAs using 126 plasmids containing 3' ribozyme sequences that generate discrete 3' ends. We measured 127 IFN-I response after transfection with these RNAs, confirming the difference observed 128 earlier between RNY4 and RNY4ΔS3 ( Fig. S2C ). Finally, to confirm that endogenously 129 transcribed Y-RNAs can be immunostimulatory, we cloned the RNY4 sequence 130 downstream of an RNA Pol3 promoter (U6) and used a Pol2 promoter (CMV) as control. 131
Only endogenous transcription of RNY4 driven by RNA Pol3, but not when driven by Pol2, 132 elicited an IFN-I response dependent on the RIG-I/MAVS pathway ( Fig. 2C ). To further 133 understand the novel function of Y-RNAs as a RIG-I agonist, we created a secondary 134 structure model of RNY4 and computed the probability of different sets of sequences of 135 viral or human origins to fold along this model. Strikingly, RNY4-like structures were more 136 often predicted in the 5' end of positive-sense RNA virus genomic sequences than in 137 human RNA families, and specifically in sequences from Flaviviridae virus family ( Fig.  138 2D). Altogether, these results suggest that Y-RNAs from the subfamily HY4 display 139 patterns of endogenous viral mimicry and can be mobilized as RIG-I agonists upon 140 infection. 141
DUSP11 modulates RNY4 5'-PPP and is downregulated by HIV-1 VPR
As Y-RNAs are readily expressed at steady-state, we questioned what triggers their 143 immunogenicity upon viral infection. Our results indicate that a 5'-PPP end is required for 144 RNY4 RIG-I agonist activity. We performed a differential enzymatic digestion assay (Fig. 145 S3A) to analyze the 5' structure of RNAs in HIV-1-infected Jurkat T cells. Surprisingly, 146
HIV-1 infection induced a hyper triphosphorylation of RNY1 and RNY4 compared to non-147 infected cells (Fig. 3A) . Every Pol3-transcribed RNA initially contains a 5'-PPP upon 148 transcription that can be further edited by different cellular enzymes. Among these, 149 DUSP11 is a protein from the dual-specificity phosphatase family that displays 5'-150 triphophatase activity on several miRNA and other cellular noncoding RNAs (19, 20) . We 151 generated DUSP11 knock-out Jurkat cells to analyze its activity on Y-RNAs. Deletion of 152 DUSP11 led to a notable increase in 5'-PPP levels at RNY4 5'-end compared to WT cells, 153
as previous results suggested (20) (Fig. S3B, S3C ). Further, infection with an HIV-1 NL4.3 154 clone coding for GFP (HIV-GFP) led to profound DUSP11 downregulation in Jurkat and 155 primary CD4 T cells ( Fig. 3B -C). The predominantly nuclear localization of DUSP11 (21) 156 and the rapid downregulation kinetics observed upon HIV-1 infection led us to hypothesize 157 that HIV-1 viral protein R (VPR) could be responsible for the observed effect on DUSP11 158 levels. VPR codes for a conserved accessory protein that incorporates into viral particles, 159 has nuclear transport ability and induces the proteasomal degradation of several host cell 160 factors (22). We compared DUSP11 downregulation in Jurkat T cells infected by either 161 WT HIV-1 or the same clone lacking VPR (HIVΔVPR). We found that VPR expression 162 was required for HIV-1-induced DUSP11 downregulation ( Fig. 3D ). Concordantly, 163 expression of WT VPR after transduction by lentiviral vectors, but not of a VPR(Q65R) 164 mutant unable to recruit the DCAF1/DDB/Cul4 ligase complex (23), was sufficient to 165 induce DUSP11 downregulation in Jurkat (Fig. S3D) . 166
Since DUSP11 dephosphorylates the 5' end of putative endogenous RIG-I ligands, we 167 analyzed whether DUSP11 deficiency was sufficient to trigger an innate immune response 168 by performing total RNAseq on WT and DUSP11 -/-Jurkat clones. A large fraction of 169 differentially expressed genes were interferon-regulated genes, as annotated in the 170 interferome database (24) ( Fig. 3E ). We further validated by qPCR the upregulation of 171 genes from a panel of classical type-I ISGs (Fig. S3E ). Additionally, we confirmed the 172 upregulation of mRNAs coding for T cell surface markers involved in T cell activation and survival such as CD28, CD38 or IL7R that we found differentially expressed by RNAseq 174 ( Fig. S3E ). Finally, we defined a gene signature associated with DUSP11 deficiency in T 175 cells composed of the top 100 most significantly upregulated genes (Table S3) . 176 To better characterize the relevance of DUSP11 in HIV-1 infection, we infected primary 179 cells from 3 healthy donors with HIV-GFP, FACS-sorted the productively infected fraction 180 (GFP+) and performed total RNAseq on GFP+ and GFP-fractions. We computed the 181 DUSP11 -/signature established in Jurkat (Table S3 ) on HIV-1 infected cells (GFP+) and 182 compared it to non-(productively) infected cells (GFP-). Importantly, the DUSP11 -/-183 signature was sufficient to cluster both cell populations, independently of donor origin ( Fig.  184 4A). We next interrogated the presence of a transcriptional signature similar to that caused 185 by DUSP11 deficiency in HIV-1 patients. In a cohort of HIV-1 positive (HIV+) patients, for 186 which PBMCs were collected prior to and 6 months after antiretroviral treatment (ART) 187 (Table S4 )(25), we performed total RNAseq on CD4+ T cells from HIV+ patients prior to 188 ART and also found that the DUSP11 -/gene signature was sufficient to cluster HIV+ 189 patients from non-infected controls (Fig. 4B ). Moreover, DUSP11 protein levels were 190 significantly increased in 5/6 patients after antiretroviral treatment ( (1, 3, 6, 10, 11, 26, 27) . In this work, we specifically identified the repeat family of Y-RNAs, 203 and in particular RNY4, as a model of endogenous RNAs whose unique structure confers 204 a previously unknown function as RIG-I agonists. We observed a contribution of Y-RNAs 205 in RLR signaling during infections by MV and DV-4, both RNA viruses replicating in the 206 cytoplasm and producing RLR-specific viral RNA ligands (15, 16) . MV and DV-4 are acute 207 viral infections where the speed of host response is critical to halt and ultimately clear viral 208 replication. We speculate that the viral-mimicking structure of these endogenous RLRs 209 ligands licenses them to act as innate immune guardians that prime immune responses 210 at the onset of cell infection. 211
DUSP11 downregulation and subsequent transcriptional response is
We observed the same contribution of Y-RNAs during infection by HIV-1 where we failed 212 to detect any ligand of viral origin to either RIG-I, or MDA5, or LGP2. Further, we identified 213 the cellular triphosphatase DUSP11 as a key immune modulator that prevents 214 unwarranted sensing of cellular RNAs in heathy cells. Importantly, we show that HIV-1 215 has evolved mechanisms to manipulate and subvert this process through a targeted, VPR-216 dependent, degradation of DUSP11, leading to the subsequent activation of RIG-I by 217
cellular RNAs (Fig. S4 ). While we cannot exclude that other functions associated with 218 DUSP11, such as the maturation of miRNA (20, 21), might explain the selection forces 219 leading to its targeting by HIV-1, we can also speculate that RLR activation by Y-RNAs 220 may act as a rapid response mechanism for hosts to detect viruses that degrade DUSP11. 221
Importantly, during the chronic phase of HIV-1 infection, higher levels of IFN-I signaling 222 correlate with sustained levels of inflammation, immune exhaustion, CD4 T cell depletion 223 and disease progression (28). In fact, chronic IFN-I signaling is considered by many as 224 central to HIV-1 pathogenesis, to the point where the use of IFN-I blockade treatment is 225 discussed as a supplement during ART (29). In this context, it will be important to 226 determine whether, and to which extent, the immune activation subsequent to DUSP11 227 downregulation participates to the disruption of immune system homeostasis observed in 228
HIV-1-infected patients. Finally, our results emphasize the contribution of PRRs in sensing 229 not only microbial ligands but also self-derived ligands. In the context of host-pathogen 230 interactions, these endogenous ligands, possibly owing to their molecular mimicry of 231 pathogen-associated features, constitute a new class of immunostimulatory molecules 232 that provide the host the unique advantage to control both their potency and accessibility 233 cells expressing CCR5) were used for co-culture with 293-4x4 and were cultured as 310 described in (1). Primary T cells were maintained in RPMI supplemented with 5% pooled 311 human serum (Gimini Bio-products) and HEPES buffer, non-essential amino acids, PS 312
and L-glutamine (all Life Technologies). One-STrEP-tagged RLRs (ST-RLR: ST-RIG-I, 313
ST-MDA5, ST-LGP2), CHERRY (ST-CH) cells (described in (2)) and STING-37 cell line 314 corresponded to HEK293 cells stably transfected with an ISRE-luciferase reporter gene 315
(described in (3) Affinity chromatography of RLR-RNP complexes and RNA extraction.
344
ST-RLR cells were infected with MV (MOI=1) or DV-4 (MOI=0.5) for 24 hr or left uninfected 345 (NI). In the case of HIV-1, ST-RLR4X4 (tagged) cells were co-cultivated with HIV-1-346 infected cells MT4C5 cells as described in (1). Briefly, 5.10 7 MT4C5 (donor cells) were 347 exposed 150ng (equivalent p24) of HIV-1 NL4.3 for 2hr at 37°C. After washing the virus, 348
the cells were grown for 48h. The infection was monitored by flow cytometry analysis by 349
intracellular Gag staining. Infection was then performed via coculture of ST-RLR4X4 cells 350
and MT4C5 cells at a donor:target cell ratio of 1:1. 24 h post infection, cells were lysed 351
and affinity purification of ST-tagged proteins and RNA extraction was performed as 352 described in (2, 4). 353
Isolation of primary cells 354

Isolation of T cells from healthy donors 355
PBMCs were prepared by Ficoll (GE Healthcare) gradient centrifugation from buffy coats 356 received from New York blood center (Long island city, NY, USA Technologies) and CD4+ cell purity was assessed by flow cytometry. 363
Isolation of T cells from HIV-1 cohort patients 364
Frozen PBMC from a cohort of intravenous drug using HIV-1+ patients (described in(5)) 365
were thawed at 37 o C and dead cells were removed through Annexin V beads-mediated 366 selection (EasySep Dead Cell Removal Annexin V Kit, Stemcell technology). CD4+ T cells 367
were further isolated through beads-mediated negative selection (EasySep Human CD4+ 368
T cell Isolation Kit, Stemcell technology) and resuspended in Trizol (Ambion) (a small 369 fraction was resuspended in PBS to check viability and purity by flow-cytometry). After 370 addition of chloroform and phase separation, the top aqueous phase was used to 371 subsequently isolate cellular RNA and the bottom organic phase was used to purify 372 cellular proteins. Metadata of the cohort patients is listed in Table S5 . 373
In vitro transcription 374
In vitro transcribed (IVT) RNAs were generated using T7 RiboMAX express large-scale 375
RNA production system (Promega), using oligoDNA containing the sequence of interest 376 behind a T7 promoter. responses to virus infection, cells were infected 24h later with MV (MOI 1) or DV-4 (MOI 397 0.5), or co-cultured with MT4C5 infected with HIV-1 at a donor:target cell ratio of 1:1. 24h 398 later cells were lysed (Passive Lysis buffer, Promega) and Firefly luciferase and Renilla 399
Luciferase activities were measured using Dual Luciferase Reporter Assay system 400 (Promega). Renilla values were used as transfection normalization control. Low molecular 401
weight and high molecular weight poly(I:C) (Invivogen) were used as positive control of 402 activation at a concentration of 5 and 30 ng/ml, respectively. 403 STING-37 assay. STING-37 cells, corresponding to HEK293 cells stably transfected with 404
the ISRE-luciferase reporter gene (described in (3)) were plated in 24-well plates. 24h 405 later, cells were transfected with 5-20 ng/well of in vitro transcribed RNA using 406 lipofectamine 2000 (Invitrogen). 24h after transfection, cells were lysed (Passive Lysis 407 buffer, Promega) and Firefly luciferase activity was measured using the Bright-Glo 408
Luciferase Assay System (Promega). 409
Infection with virus / transduction with vector
410
HIVNL4.3-GFP, HIVNL4.3WT and HIVNL4.3ΔVPR (described in (6, 7) ) were freshly produced 411 through transfection (Polyjet, Signagen) of 293T cells with plasmids coding for the full-412 length viral genomes. 3 rd generation lentiviral vectors coding for ovalbumin (control) or 413
VPR WT or a Q65R VPR mutant were produced through co-transfection of 293T cells with 414 4 plasmids coding for Gag/Pol (Addgene #12251), Rev (Addgene #12253), VSVg 415 (Addgene #12259), or one of the transgenes mentioned above (this article) at a molar 416 ratio of 1/1/1/2.6. 48h after transfection, supernatants were collected, spun down and 417 filtered to removed cellular debris and used to infect (HIV) or transduce (lentiviral vectors) 418
T cell (Jurkat or Primary cells) by spinoculation in 96-wells plate (1,200 x g, 90 min at 419 16 o C) with polybrene (4 μg/ml, EMD Millipore). 6h after infection / transduction, 420
supernatants were replaced with fresh medium. In the case of primary cells, CD4 T cells 421
were activated using PHA-L (2 μg/ml) for 72h prior to infection. 422
When specified, HIV-GFP productively-infected cells were sorted based on the GFP 423 expression on a FACS aria (BD biosciences) with biosafety cabinet facility. The cells were 424 stained for CD3 and CD4 expression to identify CD4 T cell populations and CD8, CD14, 425
CD19 and CD56 to identify other contaminating immune cell populations. Viable cells were 426 discriminated with a viability dye (blue fluorescent dye, Thermofischer). CD3 + CD4 +/dim 427 GFP + cells were sorted as infected and the CD3 + CD4 + GFPcells were sorted as non-428
infected to the collection tube and used for RNA and protein isolation. The MV-Schwarz 429 vaccine strain (GenBank accession no. AF266291.1) has been previously described (8) .
430
DV-4 strain Dominica (AF326825) (9) was obtained from the Centro de Ingeniería Genética 431 y Biotecnología (CIGB), Cuba. 432 Differential 5'-PPP RNA digestion 433 1ug of total cellular RNA was treated with RNA 5' polyphosphatase (enzyme that converts 434 5´-triphosphorylated RNA into 5´-monophosphorylated RNA, Lucigen) for 30 min at 37 o C 435 or mock-treated. RNAs were then purified and treated with Terminator™ 5'-Phosphate-436
Dependent Exonuclease (processive 5´ to 3´ riboexonuclease that specifically digests 437
RNA with 5´-monophosphate ends, Lucigen) for 90 min at 30 o C or mock-treated. Resulting 438
RNAs were then purified and processed for qPCR analysis. 439
RNA purification 440
Total cellular RNA was extracted using Trizol-Chloroform phase separation (Ambion) 441
followed by RNA purification from the aqueous phase using a modified version of the 442
Zymo RNA Clean and Concentrator (Zymo Research), through the addition of 2x volumes 443 of ethanol to increase the retention of small RNA species. RNA was then subjected to 444
DNAse digestion (TURBO DNA-free Kit, Invitrogen) then purified again using Zymo RNA 445
Clean and Concentrator and finally resuspended in DPEC-treated water. 446
Quantitative PCR 447 1ug of total RNA was converted to cDNA using RNA to cDNA EcoDry Premix Double 448
Primed (Clontech) and resulting cDNA was diluted 10X in water. For differential enzymatic 449 digestion analysis, qPCR reactions were carried out in 10 μl reaction volumes with 5 μl of 450
TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific), 2 μl of Primers/Probe mix 451 and 3 μl of each cDNA sample. For all other analysis, qPCR reactions were carried out in 452 10μl reaction volume with 5 μl iTaq Universal SYBR Green Supermix (Bio-rad), 2 μl Primer 453 mix and 3 μl of each cDNA sample. The qPCR reactions were run using a CFX384 Touch 454
Real-Time PCR Detection System (Bio-Rad) in clear wells plates. Targets amplification 455
were quantified using the ΔΔCt method relative to β-actin. The list of the primers used in 456
this study is provided in Table S7 . 457
Western Blotting
458
Whole-cell lysates were resuspended in Laemmi sample buffer (Bio-rad) completed with 459 10% β-mercaptoethanol and heated for 5 minutes at 95 o C. 10-15ul of lysates were loaded 460 onto 10% or 4-12% mini-protean TGX gels (Bio-rad) and the gel was run in 461
Tris/Glycine/SDS buffer (Bio-rad). Proteins were transferred to 0.45 um PVDF 462 membranes (Immobilon) in Tris/Glycine buffer (Bio-rad) supplemented with 20% 463 methanol. Membranes were blocked in Tris-buffered saline (Bio-rad) plus 0.1% Tween 20 464 (Fisher) (TBS-T) containing 5% non-fat dry milk for 30 min at room temperature followed 465 by overnight incubation with primary antibody at 4 °C. Membranes were then washed with 466 TBS-T and incubated with HRP-conjugated secondary antibodies for 3 h at room 467 temperature. Membranes were then washed and HRP was activated with ECL Plus 468
Western Blotting Substrate (Pierce) for 5 minutes before being exposed to CL-Xposure 469
Film (Thermo scientific). Relative HRP signals were quantified using image Lab software 470
(Bio-rad), relative to GAPDH or Tubulin controls. 471
Antibodies 472
Western Blot and Protein purification. 473
The following antibodies were used: HIV-1 p24 (mouse monoclonal, Abcam, clone 474 39/5.4A, #ab9071); MAVS (rabbit polyclonal, Cell Signaling Technology -CST, #3993); 475 DUSP11 (rabbit polyclonal, Proteintech, #10204-2-AP); α-tubulin (mouse monoclonal, 476
Proteintech, clone 1E4C11, #66031-1-Ig); HIV-1 gp120 (sheep polyclonal, gift from 477 Benjamin Chen laboratory); GFP (rabbit monoclonal, CST, clone D5.1, #2956); GAPDH 478
(rabbit monoclonal, CST, clone 14C10, #2118); VPR (rabbit polyclonal, Proteintech, # 479
51143-1-AP), StrEP-Tag (mouse monoclonal, Qiagen, #34850). Peroxidase-conjugated 480 secondary antibodies against rabbit IgG (#7074) and mouse IgG (#7076) were purchased 481 from CST. 482
Flow Cytometry 483
The following antibodies were used: anti-p24-FITC (mouse monoclonal, Beckman and 484
Coulter, #KC-57); anti-CD3-Pacific Blue( mouse monoclonal, Biolegend #300330); anti-485
CD4-PE (mouse monoclonal, Biolegend, #300539); anti-CD19-APC (mouse monoclonal, 486
Biolegend #302212); anti-CD14-APC (mouse monoclonal, Biolegend, #325608); anti-487 CD56-APC (mouse monoclonal, Biolegend, #318310); anti-CD8-PerCP/Cy5.5 (mouse 488 monoclonal, Bdbiosciences, #341051). 489
RNA-seq analysis of total and RLR-bound RNA
490
Protocols for NGS library preparation and NGS of total and RLR-bound RNA from MV, 491
DV-4-infected cells have been described in (2, 4) . Before RNA-seq analysis of total and 492 RLR-bound RNA from HIV-1-and mock-infected cells, depletion of ribosomal RNA was 493 done using the riboZero reagents included in the TruSeq stranded total RNA library prep 494 kit (#20020596, Illumina). NGS libraries were generated following the manufacturer's 495
protocol. The indexed samples were multiplexed per 4 or 6 and sequenced on a 496
HiSeq2500 sequencer (Illumina) to produce single-ends 65 bases reads, bearing strand 497 specificity. 498
Bioinformatics analysis of NGS reads was performed using the RNA-seq pipeline from 499
Sequana (10). Reads were cleaned of adapter sequences and low-quality sequences 500 using cutadapt (11) version 1.11. Only sequences at least 25 nt in length were considered 501 for further analysis. STAR version 2.5.0a (12) with default parameters, was used for 502 alignment on the reference genome (Human genome hg19 from UCSC). Genes were 503 counted using featureCounts version 1.4.6-p3(13) from Subreads package (parameters: 504 -t gene -g ID -s 1). For statistical analysis of NGS data, count data were analyzed using 505 R version 3.5.1 and the Bioconductor package DESeq2 version 1.20.0 (14). The 506 normalization and dispersion estimation were performed with DESeq2 using the default 507 parameters and statistical tests for differential expression were performed applying the 508 independent filtering algorithm. For each virus, a generalized linear model including the 509 replicate, beads and protein factors as well as the beads x protein interaction was set in 510 order to test for the differential expression between the biological conditions. For each 511 pairwise comparison, raw p-values were adjusted for multiple testing according to the 512
Benjamini and Hochberg (BH) procedure (15) and genes with an adjusted p-value lower 513 than 0.05 were considered differentially expressed. Bioinformatics analysis of NGS reads 514
for viral reads was performed as described in (4). The MV-Schwarz vaccine strain 515 (AF266291.1), DV-4 strain Dominica (AF326825) and HIV-1 NL4.3 (AF324493.2) were 516 used as references. 517
Protocols for NGS library preparation of Ribo-depleted total cellular RNA were performed 519 by Genewiz. Raw Illumina reads were trimmed using trim_galore (Babraham 520 bioinformatics) and cutadapt (11) version 1.18 with default settings. Reads were then 521 mapped to the human genome (gencode annotation, build 38) and to repbase elements 522 (release 20) using STAR aligner (12) version 2.6.1c. Aligned reads were assigned to 523 genes using the featureCounts function of subread package using the annotation (16). 524
This produced the raw read counts for each gene. Mapping and counting of the reads 525
were done in two stages. First, reads were mapped to the human genome, and the counts 526
were determined using the gencode annotation and the annotation derived from the 527 repeatmasker output. Second, the reads which were not assigned to any feature in either 528 gencode or repeatmasker annotation were re-aligned to the repeat consensus sequence 529
(repbase). Counts obtained from repeatmasker and repbase corresponding to the same 530 family were added together. Differential expression analysis was performed using 531
DESeq2 package (14). 532
Polymerase-III transcript annotation:
533 Identification of regions of genome transcribed by polymerase-III (Pol3) remains a topic of 534 active research (17, 18) . In order to check if a given transcript is transcribed by Pol3 for 535 our analysis, we created a curated list of tentative ncRNA transcripts that are likely 536 transcribed by Pol3. In the list, we included all ncRNA families that are known to be 537 transcribed by Pol3 (18) as well as ncRNA from hg19 genome assembly which overlap or 538 are in proximity of an annotated Pol3 binding site or known Pol3 transcript, as based on 539 curation of published datasets from Pol3 transcription studies from Refs (19-23). 540
Modeling RNY4-like structure in transcripts: 541 We follow the computational approach originally conceived in the work(24) to find Y-RNA 542 homologs in genomes and used the RNAMotif tool to identify motifs that fold into a Y-RNA 543 like structure. The RNAMotif software searches given RNA sequences for regions that are 544 able to fold into a specified secondary structure. It identifies all regions in the RNA 545 sequence capable of adopting the specified structure and calculates the free-energy 546 contribution of the RNA region folded into the structure using the nearest-neighbor model 547
for RNA(25). For our study, we use the following constraints for the "RNY4" structure 548 search with RNAMotif. The motif is required to consist of (annotation illustrated as in Fig.  549 S2B): stem (S1) of length ranging from 5 to 13 base pairs, a loop (L1) (with 0 to 2 unpaired 550 nucleotides on 5'side and 1 to 3 nucleotides on 3' end side), followed by a stem (S2) of 551 length from 7 up to 11 base pairs, with a loop (L2) of size 6 to 17 unpaired nucleotides on 552 the 5' end side and 6 to 17 nucleotides on the 3'-end side, and a stem (S3) of length 7 to 553 17 base pairs, with a terminal hairpin loop of length ranging from 3 to 10 bases. In each 554 stem, we allow up to 1 mismatch, and the stem base-pairs can contain both Watson-Crick 555
and wobble base pairs. We only search for presence of the motif at the 5' start of the 556 transcripts, so for the evaluated sequences, we only consider the motif to be present if a 557 possible RNY4 like structure (with assigned free energy by Turner model(25) smaller than 558 0) is detected by RNAMotif within 6 bases from the 5'-end of the transcript. 559
The sequence datasets evaluated for RNY4 motif presence were the following: human 560 cDNA and non-coding RNA sequences (from hg38 reference genome assembly), 561 complete genomes of positive-sense viruses with human host (Table S8, obtained from  562 NCBI viral genome database(26)), and inserts in genome that were annotated as 563 belonging to Y-RNA family in the repetitive DNA element database (27) . For each 564 sequence, we also constructed a scrambled sequence, which was obtained by randomly 565 permuting all nucleotides in the respective sequence, so that the frequency distribution of 566 respective nucleotides remains the same, but their order is random. The set of scrambled 567
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